Adult stem cells for chronic lung diseases

Respirology

Volumn 18, Issue 7, 2013, Pages 1041-1046

  Mora, Ana L ^b   Rojas, Mauricio ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

Author keywords

ageing; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; lung; mesenchymal stem cell

Indexed keywords

BLEOMYCIN; CD34 ANTIGEN; CD45 ANTIGEN; CELL SURFACE MARKER; COLLAGEN; COLLAGEN TYPE 1; DNA; FIBRONECTIN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SURFACTANT PROTEIN C; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA;

ADHERENT CELL; ADULT STEM CELL; AGING; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SELECTION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DISEASE ASSOCIATION; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA METHYLATION; EXHAUSTION; FATIGUE; FIBROBLAST; FIBROSING ALVEOLITIS; FUNCTIONAL DISEASE; GENOME; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG INJURY; MESENCHYMAL STEM CELL; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PARABIOSIS; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; RISK FACTOR; STEM CELL; TELOMERE;

AGEING; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MESENCHYMAL STEM CELL;

ADULT STEM CELLS; AGING; ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; LUNG; LUNG DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY FIBROSIS;

EID: 84884876178     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12112     Document Type: Review

References (45)

1. Augustine JJ,. Thanks, I'll stay here. A hypoglycemic episode is quickly resolved-but what about transport? EMS Mag. 2008; 37: 9-40.
2. Faner R, Rojas M, Macnee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186: 306-313.
3. Kapetanaki MG, Mora AL, Rojas M,. Influence of age on wound healing and fibrosis. J. Pathol. 2013; 229: 310-322.
4. Chilosi M, Poletti V, Rossi A,. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir. Res. 2012; 13: 3-12.
5. Lee S, Sharma K,. The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr. Rheumatol. Rep. 2004; 6: 141-148.
6. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
7. Burnham EL, Taylor WR, Quyyumi AA, et al. Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am. J. Respir. Crit. Care Med. 2005; 172: 854-860.
8. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl Acad. Sci. U.S.A. 2003; 100: 8407-8411.
9. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am. J. Respir. Cell Mol. Biol. 2005; 33: 145-152.
10. Wang G, Bunnell BA, Painter RG, et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 186-191.
11. Spees JL, Olson SD, Ylostalo J, et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc. Natl Acad. Sci. U.S.A. 2003; 100: 2397-2402.
12. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293: L131-141.
13. Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128: 5181-5188.
14. Liang Z, Zhan W, Zhu A, et al. Development of a unique small molecule modulator of CX. PLoS ONE 2012; 7: e34038.
15. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 2004; 113: 243-252.
16. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 2004; 114: 438-446.
17. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588-594.
18. Stolzing A, Jones E, McGonagle D, et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev. 2008; 129: 163-173.
19. Bork S, Pfister S, Witt H, et al. DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010; 9: 54-63.
20. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM,. Self-renewal and differentiation capacity of young and aged stem cells. Exp. Cell Res. 2008; 314: 1937-1944.
21. Choumerianou DM, Martimianaki G, Stiakaki E, et al. Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults. Cytotherapy 2010; 12: 881-887.
22. Zhou S, Greenberger JS, Epperly MW, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008; 7: 335-343.
23. Lavasani M, Robinson AR, Lu A, et al. Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. Nat. Commun. 2012; 3: 608-620.
24. Fan M, Chen W, Liu W, et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. 2010; 13: 429-438.
25. Hermann A, List C, Habisch HJ, et al. Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. Cytotherapy 2010; 12: 17-30.
26. Walenda T, Bork S, Horn P, et al. Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J. Cell. Mol. Med. 2010; 14: 337-350.
27. Khan M, Mohsin S, Khan SN, et al. Repair of senescent myocardium by mesenchymal stem cells is dependent on the age of donor mice. J. Cell. Mol. Med. 2011; 15: 1515-1527.
28. Guillot PV, Gotherstrom C, Chan J, et al. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 2007; 25: 646-654.
29. Baxter MA, Wynn RF, Jowitt SN, et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
30. Yang DQ, Halaby MJ, Zhang Y,. The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 2006; 25: 4613-4619.
31. Zeng Y, Lai O, Shen B, et al. A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA. Orthopedics 2011; 34: 261-270.
32. Patel S, Mason RM, Suzuki J, et al. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am. J. Nephrol. 2006; 26: 381-387.
33. Burns WC, Kantharidis P, Thomas MC,. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007; 185: 222-231.
34. Booth AJ, Wood SC, Cornett AM, et al. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J. Pathol. 2011; 226: 609-618.
35. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-868.
36. Yamashita T, Oda T, Sekimoto T,. [Fanconi anemia-genotoxic stress and senescence of hematopoietic stem cells]. Nihon Rinsho 2008; 66: 477-482.
37. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355-361.
38. Xu J, Gonzalez ET, Iyer SS, et al. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice. J. Gerontol. 2009; 64: 731-739.
39. Torres-Gonzalez E, Bueno M, Tanaka A, et al. Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2012; 46: 748-756.
40. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 11002-11007.
41. Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J. 2005; 19: 854-856.
42. Taraseviciene-Stewart L, Voelkel NF,. Molecular pathogenesis of emphysema. J. Clin. Invest. 2008; 118: 394-402.
43. Murray CJ, Lopez AD,. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
44. Zhen G, Liu H, Gu N, et al. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front. Biosci. 2008; 13: 3415-3422.
45. Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled randomized trial of mesenchymal stem cells in chronic obstructive pulmonary disease. Chest 2012. doi: 10.1378/chest.12-2094.